Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Clopidogrel Stories

2014-04-02 08:32:38

BRANFORD, Conn., April 2, 2014 /PRNewswire/ -- New Haven Pharmaceuticals, Inc. (the "Company"), a privately held specialty pharmaceuticals company, today announced the appointment of Larry Dillaha, M.D., to the newly-created position of Executive Vice President Operations. Dr. Dillaha joins the Company from Insys Therapeutics, Inc. (Nasdaq: INSY) where he served as Chief Medical Officer since April 2010. "We are delighted to welcome Larry, who will provide significant insight and...

2014-03-21 16:23:29

NEW YORK, March 21, 2014 /PRNewswire/ -- Pomerantz LLP has filed a class action lawsuit against The Medicines Company ("Medicines" or the "Company") (NASDAQ: MDCO) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 2:33-av-00001, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Medicines securities between February 20, 2013 and February 12, 2014 both dates...

2014-03-18 23:33:25

Rapid CYP2C19 Testing for Personalized Antiplatelet Therapy in 600-Patient Clinical Trial with Spartan Bioscience (PRWEB) March 18, 2014 Spartan Bioscience today announced the start of a 600-patient study of personalized medicine for cardiac stent patients in Germany. The study is part of a larger clinical trial entitled “Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes Trial (TROPICAL-ACS)”. TROPICAL-ACS, led by principal...

2014-03-03 16:25:40

SAN DIEGO and PARSIPPANY, N.J., March 3, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of The Medicines Company (NASDAQ: MDCO) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between February 20, 2013 and February 12, 2014 (the "Class...

2014-01-16 16:24:28

RARITAN, N.J., Jan. 16, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted against the approval of the use of XARELTO(®) (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS) in combination with standard antiplatelet therapy. Janssen is seeking approval of...

2013-12-12 23:28:53

Rapid CYP2C19 Testing for Heart Attack Patients Using Antiplatelet Drugs in 150-Patient Clinical Trial With Spartan Bioscience Ottawa, Ontario (PRWEB) December 12, 2013 Spartan Bioscience today announced the start of a 150-patient study of personalized medicine for cardiac stent patients in Poland, Hungary, and Lithuania. The study is sponsored by the Medical University of Warsaw, and is entitled “Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During...

2013-11-26 23:30:44

Spartan Bioscience announces 2,000-patient clinical trial of rapid DNA testing for heart attack patients using antiplatelet drugs. Ottawa, Ontario (PRWEB) November 26, 2013 Spartan Bioscience today announced the start of a 2,000-patient study of personalized medicine for cardiac stent patients in Saudi Arabia. The study is sponsored by the University of Dammam, and is entitled “Bedside Testing of CYP2C19 Gene for Treatment of Patients with PCI with Antiplatelet Therapy.” The Spartan...

2013-11-26 12:26:55

DUBLIN, Nov. 26, 2013 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/h45rfk/the_medicines) has announced the addition of the "The Medicines Company's Cangrelor - Is it better than Plavix for Acute Coronary Syndrome?" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Cangrelor is a reversible, intravenous inhibitor of the P2Y12 receptor whose effect is to inhibit adenosine diphosphate-induced platelet aggregation. The...

2013-11-13 08:29:34

Researchers cite prescriber uncertainty about interpreting pharmacogenetic test results WOONSOCKET, R.I., Nov. 13, 2013 /PRNewswire/ -- A new study conducted by researchers at CVS Caremark (NYSE: CVS) and Brigham and Women's Hospital explores the impact of genetic testing on prescribing patterns for cardiovascular therapy. The study, published in the November issue of the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes, found that only one in...

2013-10-29 12:24:21

Despite Market Constraints in Russia, Multinational Corporations Will Enjoy Significant Sales Growth for Key Products, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the acute coronary syndrome (ACS) market in Russia will grow at an annual rate of more than five percent, reaching...